Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 18/20 | 0.46 |
| ▸ | ARG2 | P78540 | 18/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894260 | 1.00 | ARG1 (0.46) | ARG1ARG2HDAC6ADORA3ADORA2A | |
| SCHEMBL894261 | 1.00 | ARG1 (0.46) | ARG1ARG2HDAC6ADORA3ADORA2A | |
| Hydrochloric Acid SCHEMBL895194 | 0.99 | ARG1 (0.46) | ARG1ARG2HDAC6ADORA3ADORA2A | |
| Hydrochloric Acid SCHEMBL895195 | 0.99 | ARG1 (0.46) | ARG1ARG2HDAC6ADORA3ADORA2A | |
| Hydrochloric Acid SCHEMBL2566685 | 0.99 | ARG1 (0.46) | ARG1ARG2HDAC6ADORA3ADORA2A | |
| SCHEMBL20683513 | 0.90 | HDAC6 (0.40) | HDAC6ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL895085 | 0.85 | ARG1 (0.52) | ARG1ARG2 | |
| SCHEMBL30169939 | 0.85 | ARG1 (0.52) | ARG1ARG2 | |
| SCHEMBL895087 | 0.85 | ARG1 (0.52) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL2577972 | 0.84 | ARG1 (0.51) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023283332-A1 | USES OF ARGINASE INHIBITORS FOR MANAGING KIDNEY DISEASE AND CARDIOVASCULAR CONDITIONS | EMORY UNIVERSITY (US) | 2023-01-12 | — | — | WO | disclosed |